PD-L1: A Biomarker for Cancer Immunotherapy?
Read More Stories
The American Society of Clinical Oncology
ASCO spotlights what’s next in cancer research and treatment. We’ve gathered perspectives from around the cancer community on topics people will be talking about at the meeting.
PD-L1/PD-1 Pathway: A Security Checkpoint
Dr. Dan Chen explains how cancer immunotherapy helps break the cellular camouflage of PD-L1.